CagriSema, Cagrilintide, and Semaglutide Investigated for Muscle Health Preservation During Weight Loss

While effective for weight loss, many strategies, including GLP-1R agonists, can lead to a disproportionate loss of lean muscle mass, which is detrimental to metabolic health, strength, and long-term well-being. Preserving muscle mass during weight loss is crucial for maintaining basal metabolic rate and preventing sarcopenia in individuals with obesity and prediabetes. This study explores whether the amylin analog cagrilintide, alone or in combination with the GLP-1R agonist semaglutide (as CagriSema), can offer a superior approach to weight management by specifically addressing muscle health.

This is a randomized, placebo-controlled clinical study designed to evaluate the effects of CagriSema (a co-formulation of cagrilintide and semaglutide), cagrilintide alone, and semaglutide alone on muscle health. Participants are individuals with excess body weight and slightly higher than normal blood sugar. They will be randomly assigned to receive one of the three active study medicines or a placebo. The study duration for each participant is up to 15 months. The primary endpoint is the assessment of muscle health parameters during weight loss, though specific assays or measurement methods are not detailed in this abstract.

As this is a clinical study protocol, specific results are not yet available. However, the study aims to determine if CagriSema, cagrilintide, or semaglutide can differentially affect muscle health parameters in individuals undergoing weight loss. The primary objective is to understand the "amylin signature" in muscle health, suggesting an investigation into how amylin agonism (via cagrilintide) might influence muscle preservation or function, potentially through pathways distinct from or synergistic with GLP-1R agonism. Researchers will likely measure changes in lean body mass, muscle strength, and physical performance, though the abstract does not specify these endpoints or any numerical targets. The findings will be crucial for understanding the full metabolic impact of these therapies. > The core goal is to elucidate the role of these compounds in mitigating muscle loss often associated with significant weight reduction, particularly comparing the combined GLP-1R and amylin agonism of CagriSema against its individual components.